American Association for Cancer Research, Cancer Epidemiology, Biomarkers & Prevention, 2023
DOI: 10.1158/1055-9965.epi-23-1303
Full text: Unavailable
Abstract Background: Little is known about SARS-CoV-2 infection and COVID-19 severity among a growing population of cancer survivors. We describe the association of infection and related hospitalization by recency of cancer diagnosis in a large US cohort. Methods: Participants were sent electronic surveys between April 2020 and January 2021 to collect information on SARS-CoV-2 infection and potential COVID-19-related risk factors. SARS-CoV-2 infections were identified using survey report of a COVID-19-positive test and electronic health record data. Cumulative incidence of SARS-CoV-2 infection was estimated up to 365 days from baseline survey and stratified by recency of cancer diagnosis. Among those with SARS-CoV-2 infection, we used logistic regression to estimate the association between recency of cancer diagnosis and hospitalization within 30 days of infection. Results: Cumulative incidence of SARS-CoV-2 infection at 365 days was 3.3% (95%CI 3.2-3.5%) among those without cancer history and ranged from 2.8% (95%CI 2.3-3.5%) to 3.7% (95%CI 2.9-4.7%) among those with a history of cancer depending on recency. There was no statistically significant difference in odds of hospitalization within 30 days following SARS-CoV-2 infection by cancer diagnosis recency. Conclusions: Our null findings are consistent with other studies on COVID-19 infection risk in cancer survivors, where COVID-19 severity and sequelae were independent of cancer history and were likely associated with factors such as intensive care unit admission, non-cancer comorbid conditions, and long-term care residency. Impact: This study can inform COVID-19 risk-counseling of cancer survivors and their caregivers as we continue to contend with COVID-19.